Koers Carbylan Therapeutics Inc Nasdaq
Aandelen
US1413841073
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | 14,95 mln. 13,98 mln. | Marktkapitalisatie | 495 mln. 463 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -114 mln. -107 mln. | Nettowinst (verlies) 2025 * | -111 mln. -104 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 218 mln. 204 mln. | Nettoliquiditeiten 2025 * | 105 mln. 97,93 mln. | EV/omzet 2025 * | 26,1 x |
K/w-verhouding 2024 * |
-3,86
x | K/w-verhouding 2025 * |
-4,86
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,77% |
Recentste transcriptie over Carbylan Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 26-03-04 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01-08-16 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 03-05-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 01-02-19 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01-08-16 |
Albert Cha
BRD | Director/Board Member | 51 | 01-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,22% | 93,91 mld. | |
-1,32% | 38,4 mld. | |
-13,44% | 32,61 mld. | |
+76,30% | 28,2 mld. | |
-13,11% | 15,91 mld. | |
+0,68% | 14,22 mld. | |
-12,06% | 11,54 mld. | |
+185,28% | 10,74 mld. | |
-53,00% | 9,47 mld. |